Funders › MA › Alzheimer's Disease Research Foundation › 2022
Grants paid by Alzheimer's Disease Research Foundation, tax year 2022
EIN 52-2396428 · Wellesley Hls, MA · Form 990, Schedule I · NTEE H83
In tax year 2022, Alzheimer's Disease Research Foundation (EIN 52-2396428) reported 85 grants paid totaling $19,108,307. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2022
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $1,955,000 | paid | THECUREALZALZHEIMERS GENOME PROJECT | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $345,000 | paid | APOE CONSORTIUM: ROLE OF APOE ISOFORMS IN IMMUNE RESPONSES IN A MODEL OF TAUOPATHY | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $345,000 | paid | BEE: CROSSTALK OF CNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Whitehead Cambridge, MA | A | $307,500 | paid | CIRCUITS: IMPACT OF EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMERS DISEASE PATHOLOGY | 202331259349301933 |
| 2022 | Boston Children's Hospital Boston, MA | A | $300,000 | paid | NIC: UNDERSTANDING THE CONSEQUENCES OF NON-CODING AD RISK ALLELES ON MICROGLIA FUNCTION | 202331259349301933 |
| 2022 | University of California San Diego La Jolla, CA | A | $287,500 | paid | BEE: IDENTIFYING THE BLOOD-BRAIN BARRIER CHANGES DURING ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $287,500 | paid | NIC: BIOMARKER TOOL DEVELOPMENT IN CAF NEUROIMMUNE CONSORTIUM | 202331259349301933 |
| 2022 | Brigham and Women's Boston, MA | A | $287,500 | paid | APOE CONSORTIUM: APOE4-MEDIATED DYSFUNCTION OF CD8 T CELL-MICROGLIA CROSSTALK IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Weill Cornell New York, NY | A | $287,500 | paid | BEE: BIOCHEMICAL AND FUNCTIONAL ANALYSIS OF CSF AND LYMPH FOLLOWING CHANGES IN BRAIN FLUID DYNAMICS | 202331259349301933 |
| 2022 | University of Texas Southwestern Medical Center Dallas, TX | A | $287,000 | paid | ADTC: THE ROLE OF VCP/P97 IN TAU PRION REPLICATION | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $286,595 | paid | ADTC: HOW DO SOLUBLE TAU SPECIES REPLICATE? | 202331259349301933 |
| 2022 | Northwestern Chicago, IL | A | $286,357 | paid | ADTC: THE ROLE OF A-INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $252,077 | paid | APOE: ASSESSING THE ADDED DIAGNOSTIC VALUE OF PERIPHERAL APOE PROTEIN LEVELS IN CURRENT BLOOD-BASED BIOMARKER ASSAYS FOR CNS AMYLOIDOSIS | 202331259349301933 |
| 2022 | University of California Irvine Irvine, CA | A | $250,000 | paid | NIC: EXAMINING THE ROLE OF HUMAN MICROGLIA IN THE TRANSITION BETWEEN PARENCHYMAL AND VASCULAR BETA-AMYLOID PATHOLOGY | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $250,000 | paid | CREATION OF A FIBROBLAST/IPS CELL BANK TO FACILITATE PERIPHERAL/BRAIN COMPARISONS, AND ALLOW MOLECULAR INVESTIGATIONS INTO MOLECULAR MECHANISMS UNDERLYING DIFFERENCES IN DISEASE AGGRESSIVENESS | 202331259349301933 |
| 2022 | University of California San Diego La Jolla, CA | A | $250,000 | paid | NIC: LEVERAGING ENHANCER LANDSCAPES TO DECODE AD RISK ALLELES IN MICROGLIA | 202331259349301933 |
| 2022 | Weill Cornell New York, NY | A | $250,000 | paid | DEVELOPMENT OF HUMAN CGAS INHIBITORS TO TREAT ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Harvard Medical School Boston, MA | A | $250,000 | paid | NIC: ASSESSING THE LINKS BETWEEN THE MS4A RISK GENES, MICROGLIA, AND ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Beth Israel Deaconess Medical Center Boston, MA | A | $248,980 | paid | CIRCUITS: AUNIFIED APPROACH TO ACTIONABLE ALZHEIMERS DISEASE SIGNATURES | 202331259349301933 |
| 2022 | Northwestern Chicago, IL | A | $246,804 | paid | SINGLE NUCLEUS RNA SEQUENCING ANALYSIS OF ACE1 R1284Q KNOCKIN MICE | 202331259349301933 |
| 2022 | University of Michigan Ann Arbor, MI | A | $243,407 | paid | NEUROBIOLOGICAL BASIS OF COGNITIVE IMPAIRMENT IN AFRICAN AMERICANS: DEEP PHENOTYPING OF OLDER AFRICAN AMERICANS AT RISK OF DEMENTIA | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $230,590 | paid | AD4: HIGH-THROUGHPUT DRUG SCREENING FOR ALZHEIMER'S DISEASE USING 3D HUMAN NEURAL CULTURE SYSTEMS | 202331259349301933 |
| 2022 | University of Connecticut Farmington, CT | A | $230,000 | paid | AD PATHOPHYSIOLOGY ALTERS THE LEVEL OF ELECTRICAL AND CHEMICAL SYNAPSE COUPLING IN THE NETWORK OF GABAERGIC PV+ INTERNEURONS EARLY IN DISEASE COURSE | 202331259349301933 |
| 2022 | University of Texas Southwestern Medical Center Dallas, TX | A | $230,000 | paid | RNA AND TAU SEED FORMATION | 202331259349301933 |
| 2022 | University of Chicago Chicago, IL | A | $229,033 | paid | TEMPORAL RELATIONSHIPS BETWEEN GUT DYSBIOSIS AND MICROGLIA CELL ACTIVATION FOLLOWING ANTIBIOTIC TREATMENT | 202331259349301933 |
| 2022 | Houston Methodist Houston, TX | A | $225,000 | paid | AD4: UNCOVERING THE MOLECULAR MECHANISM OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATICS ALZHEIMERS DRUG REPOSITIONING | 202331259349301933 |
| 2022 | University of Southern California Los Angeles, CA | A | $219,535 | paid | AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES | 202331259349301933 |
| 2022 | Mount Sinai New York, NY | A | $217,327 | paid | MICROGLIAL-SPECIFIC INPP5D KNOCKDOWN MODULATES BEHAVIOR, AMYLOIDOSIS, AND TAUOPATHY IN ALZHEIMER'S MOUSE MODELS | 202331259349301933 |
| 2022 | University of Chicago Chicago, IL | A | $210,871 | paid | IDENTIFYING THE SEX-SPECIFIC ROLES OF THE GUT-MICROBIOME-BRAIN AXIS IN A MOUSE MODEL OF AB AMYLOIDOSIS | 202331259349301933 |
| 2022 | Yale New Haven, CT | A | $204,238 | paid | BEE: CNS FLUID HOMEOSTASIS AND WASTE CLEARANCE IN ALZHEIMERS DISEASE CHARACTERIZED BY MRI | 202331259349301933 |
| 2022 | Johns Hopkins Baltimore, MD | A | $201,250 | paid | HUMAN BRAIN CD33 LIGAND, RPTPS3L, LIMITS MICROGLIAL PHAGOCYTOSIS AND CONTRIBUTES TO ALZHEIMERS DISEASE PROGRESSION | 202331259349301933 |
| 2022 | University of Southern California Los Angeles, CA | A | $201,250 | paid | PRENATAL INFLAMMATION EFFECTS ON BLOOD BRAIN BARRIER FUNCTION AND AD-RELATED PATHOLOGIES ACROSS THE LIFESPAN | 202331259349301933 |
| 2022 | University of Virginia Charlottesville, VA | A | $201,250 | paid | EXPLORING THE THERAPEUTIC POTENTIAL OF CLUSTERIN IN A PRECLINICAL MODEL OF ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Brigham and Women's Boston, MA | A | $201,250 | paid | NEUROIMMUNE CONNECTOME PERTURBATIONS IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Brigham and Women's Boston, MA | A | $201,250 | paid | TARGETING THE MICROBIOME AND INNATE IMMUNITY IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | University of California San Francisco San Francisco, CA | A | $201,250 | paid | UNDERSTANDING HOW HUMAN BRAIN VASCULAR CELLS MEDIATE GENETIC RISK FOR ALZHEIMER'S DISEASE | 202331259349301933 |
| 2022 | Mayo Jacksonville Jacksonville, FL | A | $201,250 | paid | ABCA7 LOSS OF FUNCTION IN AGING AND ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Harvard Medical School Boston, MA | A | $201,250 | paid | DISSECTING THE MODULATORY ROLES OF INTERLEUKIN-17 RECEPTOR D IN ALZHEIMER'S DISEASE | 202331259349301933 |
| 2022 | University of California San Francisco San Francisco, CA | A | $201,250 | paid | ROLE OF THE CIRCULATING EXERKINE GPLD1 IN AMELIORATING ALZHEIMERS DISEASE PATHOLOGY | 202331259349301933 |
| 2022 | Mayo Jacksonville Jacksonville, FL | A | $201,250 | paid | EVALUATING TMEM106B ACCUMULATION IN AD | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $200,417 | paid | CIRCADIAN PERTURBATIONS OF THE VASCULOME AND MICROGLIOME IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Carnegie Mellon Pittsburgh, PA | A | $200,000 | paid | CIRCUITS: INTERPRETING ALZHEIMERS DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS | 202331259349301933 |
| 2022 | Duke Durham, NC | A | $199,162 | paid | SEX DIFFERENCES IN ALZHEIMER'S DISEASE PROGRESSION: FRAMINGHAM HEART STUDY | 202331259349301933 |
| 2022 | University of Virginia Charlottesville, VA | A | $198,932 | paid | TOXIC EFFECTS OF EXTRACELLULAR TAU OLIGOMERS ON NEURONS | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $197,500 | paid | AD4: MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Boston University Boston, MA | A | $197,500 | paid | AD4: BLOCKING SYNAPTOTOXICITY IN ALZHEIMER'S 3D MODELS | 202331259349301933 |
| 2022 | Duke Durham, NC | A | $194,253 | paid | CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMERS PATHOLOGY IN MICE | 202331259349301933 |
| 2022 | Brigham and Women's Boston, MA | A | $183,562 | paid | IMMUNOTHERAPIES TARGETING THE MICROBIOTA TO PREVENT COGNITIVE DECLINE IN ALZHEIMER'S DISEASE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $177,675 | paid | G2T, AD4 AND GENERAL SCIENTIFIC SUPPORT | 202331259349301933 |
| 2022 | New York University New York, NY | A | $174,883 | paid | THE ROLE OF ASTROCYTE-DERIVED TOXIC LIPIDS MEDIATING DEGENERATION IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | University of Virginia Charlottesville, VA | A | $172,500 | paid | TARGETING A MASTER INNATE IMMUNE ADAPTOR MOLECULE IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Mount Sinai New York, NY | A | $172,500 | paid | STRESS AND NEUROVASCULAR-IMMUNE NETWORKS IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $172,500 | paid | TARGETING REACTIVE ASTROCYTES FOR THERAPEUTIC INTERVENTION OF ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Weill Cornell New York, NY | A | $172,500 | paid | IDENTIFICATION OF CD33 ANTAGONISTS | 202331259349301933 |
| 2022 | Mayo Jacksonville Jacksonville, FL | A | $172,500 | paid | HARNESSING MENINGEAL LYMPHATICS AND IMMUNITY TO ALLEVIATE APOE4-INDUCED BRAIN DYSFUNCTION | 202331259349301933 |
| 2022 | Stanford Stanford, CA | A | $172,500 | paid | A TRANSCRIPTIONAL REJUVENATION SIGNATURE FOR ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $172,500 | paid | NEURONAL SUBTYPE-SPECIFIC MODELING OF ALZHEIMERS DISEASE BY DIRECT NEURONAL REPROGRAMMING OF PATIENT FIBROBLASTS | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $172,500 | paid | EFFECTS OF DE-PALMITOYLATION AND ACAT INHIBITION ON AXONAL AB GENERATION VIA MAM-ASSOCIATED PALAPP | 202331259349301933 |
| 2022 | Tufts Boston, MA | A | $172,500 | paid | IN VIVO CHARACTERIZATION OF A LOSS OF FUNCTION GGA3 RARE VARIANT ASSOCIATED WITH AD | 202331259349301933 |
| 2022 | Mount Sinai New York, NY | A | $172,500 | paid | SYSTEMS INTEGRATION AND THERAPEUTICS TRANSLATION IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Rockefeller New York, NY | A | $172,500 | paid | STIMULATING SYNAPTIC PROTEASOME ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Unc-Chapel Hill Chapel Hill, NC | A | $172,500 | paid | SMALL MOLECULE ACTIVATORS OF PLC-Y2 AS NOVEL THERAPEUTICS FOR ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Yale New Haven, CT | A | $172,500 | paid | ROLE OF MICROGLIAL MATRICELLULAR PROTEIN SPARC IN CONTROL OF INFLAMMASOME ACTIVATION | 202331259349301933 |
| 2022 | Weill Cornell New York, NY | A | $172,500 | paid | GUT MICROBIOTA, ENDOTHELIAL DYSFUNCTION AND TAU-MEDIATED COGNITIVE IMPAIRMENT | 202331259349301933 |
| 2022 | Mount Sinai New York, NY | A | $172,500 | paid | ESTABLISHING THE MOLECULAR AND CELLULAR MECHANISMS AND BIOMARKERS OF APOE4-MEDIATED SUSCEPTIBILITY TO TAU-RELATED COGNITIVE IMPAIRMENTS | 202331259349301933 |
| 2022 | Mskcc New York, NY | A | $172,500 | paid | THE ROLE OF IFITM3 AND GAMMA SECRETASE IN MICROGLIA | 202331259349301933 |
| 2022 | Wake Forest Winstonsalem, NC | A | $172,500 | paid | INVESTIGATING THE ROLE OF TAU PROTEIN IN NEURONAL SENESCENCE INDUCTION AND MAINTENANCE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $172,500 | paid | DEVELOPMENT OF A MULTICELLULAR BRAIN MODEL TO STUDY BRAIN-VASCULAR-PERIPHERAL IMMUNE CELLS CROSSTALK INALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Brigham and Women's Boston, MA | A | $172,500 | paid | ROLE OF CHECKPOINT MOLECULE TIM-3 IN MICROGLIA REGULATION IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $172,500 | paid | REGIONAL VARIABILITY OF PATHOLOGY-ASSOCIATED PROPERTIES OF TAU IN POSTERIOR CORTICAL ATROPHY | 202331259349301933 |
| 2022 | University of California San Diego La Jolla, CA | A | $172,500 | paid | FUNCTIONAL BASIS FOR NOVEL PKC K56R MUTATION IN ALZHEIMER'S DISEASE | 202331259349301933 |
| 2022 | Weill Cornell New York, NY | A | $172,500 | paid | ROLE OF MICROGLIA IN DEGRADATION AND TRIMMING OF ALZHEIMERS AMYLOID BETA | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $172,500 | paid | CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Broad Institute Cambridge, MA | A | $171,207 | paid | REVEALING NEW GENES AND PATHWAYS AT THE INTERSECTION OF LIPOTOXIC AND GENETIC RISK FOR ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Barrow Phoenix, AZ | A | $170,877 | paid | HARNESSING BIG DATA TO UNDERSTAND ALZHEIMER'S DISEASE RISK | 202331259349301933 |
| 2022 | Boston University Boston, MA | A | $167,707 | paid | APOE CONSORTIUM: MODULATION OF SELECTIVE NEURONAL VULNERABILITY IN ALZHEIMERS DISEASE BY APOE | 202331259349301933 |
| 2022 | Baylor College of Medicine Houston, TX | A | $167,637 | paid | ELUCIDATING THE ROLE OF SOLUBLE EPOXIDE HYDROLASE AND ARACHIDONIC ACID METABOLISM IN NEUROINFLAMMATION AND ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Boston Children's Hospital Boston, MA | A | $149,500 | paid | NEUROINFLAMMATION CONTRIBUTIONS TO ALZHEIMERS DISEASE: ROLE OF THE CHOROID PLEXUS | 202331259349301933 |
| 2022 | Washington University Saint Louis, MO | A | $120,015 | paid | CHARACTERIZATION OF MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM | 202331259349301933 |
| 2022 | New York University New York, NY | A | $115,000 | paid | NIC: INVESTIGATION OF AD RISK ALLELES IN ASTROCYTES FOCUS ON CHOLESTEROL TRANSPORT AND MICROGLIA INTERACTIONS | 202331259349301933 |
| 2022 | Salk La Jolla, CA | A | $115,000 | paid | CIRCUITS: IMPACT OF EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMERS DISEASE PATHOLOGY | 202331259349301933 |
| 2022 | Albert Einstein College of Medicine Bronx, NY | A | $100,000 | paid | APPLICATION OF MACHINE LEARNING METHODS IN ALZHEIMERS DISEASE CLINICAL TRIALS | 202331259349301933 |
| 2022 | Stony Brook Stony Brook, NY | A | $82,166 | paid | BEE: CNS FLUID HOMEOSTASIS AND WASTE CLEARANCE IN ALZHEIMERS DISEASE CHARACTERIZED BY MRI | 202331259349301933 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990 e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.